Anti-HIV drugs and the mitochondria

被引:73
作者
Pinti, Marcello
Salomoni, Paolo
Andrea, Cossarizza
机构
[1] Univ Modena, Dept Biomed Sci, Sect Gen Pathol, I-41100 Modena, Italy
[2] Reggio Emilia Sch Med, I-41100 Modena, Italy
[3] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS | 2006年 / 1757卷 / 5-6期
基金
英国医学研究理事会;
关键词
mitochondria; HIV; AIDS; mitochondrial DNA; antiretroviral therapy; HAART;
D O I
10.1016/j.bbabio.2006.05.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several drugs are currently used that can significantly prolong the course of the infection with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome (AIDS). Among these drugs, the nucleosidic inhibitors of viral reverse transcriptase can alter mitochondrial (mt) function by inhibiting the mitochondrial DNA polymerase gamma (the enzyme responsible for the replication of mtDNA). Decreased mtDNA content provokes a diminished synthesis of respiratory chain enzymes, leading to alterations in rut function. These are in turn responsible for a variety of side effects frequently observed in HIV+ patients, that range from hyperlactatemia and lactic acidosis to lipodystrophy, a pathology characterized by accumulation of visceral fat, breast adiposity, cervical fat-pads, hyperlipidemia, insulin resistance and fat wasting in face and limbs. In this paper, data concerning the effects of different compounds on mitochondria, their role in the pathogenesis of lipodystrophy, and problems related to studies on the mt toxicity of antiviral drugs are reviewed and thoroughly discussed. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:700 / 707
页数:8
相关论文
共 111 条
[1]  
Ahluwalia GS, 1996, MOL PHARMACOL, V50, P160
[2]   IL-6 AND NF-IL6 IN ACUTE-PHASE RESPONSE AND VIRAL-INFECTION [J].
AKIRA, S ;
KISHIMOTO, T .
IMMUNOLOGICAL REVIEWS, 1992, 127 :25-50
[3]   DEPLETION OF MUSCLE MITOCHONDRIAL-DNA IN AIDS PATIENTS WITH ZIDOVUDINE-INDUCED MYOPATHY [J].
ARNAUDO, E ;
DALAKAS, M ;
SHANSKE, S ;
MORAES, CT ;
DIMAURO, S ;
SCHON, EA .
LANCET, 1991, 337 (8740) :508-510
[4]   Mitochondria as cell targets of AZT (zidovudine) [J].
Barile, M ;
Valenti, D ;
Quagliariello, E ;
Passarella, S .
GENERAL PHARMACOLOGY, 1998, 31 (04) :531-538
[5]   3'-Azido-3'-deoxythymidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator [J].
Barile, M ;
Valenti, D ;
Passarella, S ;
Quagliariello, E .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (07) :913-920
[6]   Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells [J].
Benbrik, E ;
Chariot, P ;
Bonavaud, S ;
AmmiSaid, M ;
Frisdal, E ;
Rey, C ;
Gherardi, R ;
BarlovatzMeimon, G .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 149 (01) :19-25
[7]   Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors [J].
Birkus, G ;
Hitchcock, MJM ;
Cihlar, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :716-723
[8]   Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[9]   Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial [J].
Carr, A ;
Workman, C ;
Smith, DE ;
Hoy, J ;
Hudson, J ;
Doong, N ;
Martin, A ;
Amin, J ;
Freund, J ;
Law, M ;
Cooper, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :207-215
[10]   HIV protease inhibitor-related lipodystrophy syndrome [J].
Carr, A .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S135-S142